A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

AC Huang, R Zappasodi - Nature immunology, 2022 - nature.com
Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Dynamics and specificities of T cells in cancer immunotherapy

G Oliveira, CJ Wu - Nature Reviews Cancer, 2023 - nature.com
Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

FJ Lowery, S Krishna, R Yossef, NB Parikh, PD Chatani… - Science, 2022 - science.org
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By map** 55 neoantigen …

From bulk, single-cell to spatial RNA sequencing

X Li, CY Wang - International journal of oral science, 2021 - nature.com
RNA sequencing (RNAseq) can reveal gene fusions, splicing variants, mutations/indels in
addition to differential gene expression, thus providing a more complete genetic picture than …

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

G Oliveira, K Stromhaug, S Klaeger, T Kula… - Nature, 2021 - nature.com
Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

[HTML][HTML] CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

N Prokhnevska, MA Cardenas, RM Valanparambil… - Immunity, 2023 - cell.com
Improvements in tumor immunotherapies depend on better understanding of the anti-tumor
T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that …

The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes

Q Huang, X Wu, Z Wang, X Chen, L Wang, Y Lu… - Cell, 2022 - cell.com
Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

BC Creelan, C Wang, JK Teer, EM Toloza, J Yao… - Nature medicine, 2021 - nature.com
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in
melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer …

Exploring immunotherapy in colorectal cancer

J Weng, S Li, Z Zhu, Q Liu, R Zhang, Y Yang… - Journal of hematology & …, 2022 - Springer
Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics

JR Giles, SF Ngiow, S Manne, AE Baxter, O Khan… - Nature …, 2022 - nature.com
Naïve CD8+ T cells can differentiate into effector (Teff), memory (Tmem) or exhausted (Tex)
T cells. These developmental pathways are associated with distinct transcriptional and …